Procaspase combination therapy for glioblastoma

US10874666B2 · kind B2 · utility

Assignees

• The Board of Trustees of the University of Illinois · US
• Vanquish Oncology, Inc. · US
• THE JOHNS HOPKINS UNIVERSITY · US

Inventors

• Paul J. Hergenrother · Champaign, US
• Rachel C. Botham · Champaign, US
• Timothy M. Fan · Mahomet, US
• Mark J. GILBERT · Seattle, US
• Michael K. Handley · Windsor, US
• Avadhut Joshi · Towson, US
• Gregory J. Riggins · Baltimore, US
• Theodore M. Tarasow · San Ramon, US

Key dates

• Filing date: Oct 1, 2018
• Grant date: Dec 29, 2020
• Expiry date: Oct 1, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.